Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8186 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves AZD8186, a selective PI3Kβ/δ inhibitor, and paclitaxel, a chemotherapeutic agent. AZD8186 targets the PI3Kβ pathway, which is often dysregulated in cancers with PTEN loss. Paclitaxel works by stabilizing microtubules, preventing cell division. The combination is explored for treating advanced gastric cancer, particularly in patients with PTEN loss.
02
Targets
MicrotubulePIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on AZD8186 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8186 + paclitaxel.